
    
      This phase 2/3 study will evaluate the efficacy and safety of ABX464 50mg QD (oral capsule),
      on treating inflammation and preventing acute respiratory failure in patients infected with
      SARS-CoV-2.

      Eligible patients will be randomized according to a 2:1 ratio into 2 treatment cohorts as
      follows:

        -  Standard of Care + Placebo cohort: 344 patients

        -  Standard of Care + ABX464 50mg QD: 690 patients

      Study design:

      The study will consist of 2 periods:

        -  Treatment phase: randomized patients will be treated for 28 days

        -  Safety follow-up phase of 14 days after which the End of Study visit (EOS) will be
           performed.
    
  